The company’s proprietary Advanced Covalent Exploration platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution.

The US company launched in October 2022 with $100 million in financing. This funding will be used to support further advancement of the company’s proprietary platform and its discovery pipeline of novel covalent molecules, initially focused on immunology.